To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy.

Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE

Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, Tex. : Landes Bioscience

Immunotherapy, Adoptive/*methods ; Neoplasms/*immunology ; Receptors, Antigen, T-Cell, alpha-beta/*immunology ; T-Lymphocytes, Cytotoxic/*immunology ; T-Lymphocytes, Regulatory/*immunology; Humans ; Lymphocytes, Tumor-Infiltrating/immunology ; Neoplasms/therapy ; Protein Engineering ; Receptors, Antigen, T-Cell, alpha-beta/genetics ; T-Lymphocytes, Cytotoxic/transplantation ; Tumor Escape/immunology

T cell adoptive therapies for immune-mediated regression of cancers have attracted a great deal of recent attention. Clinical results are glamorous, yet much remains to be uncovered behind the basic science that allows us to engineer T cells and T cell receptors (TCRs) for clinical use. We discuss the development of TCRs for therapeutic use in the context of thymic selection toward central tolerance and we review therapies based on tumor infiltrating lymphocytes (TILs), endogenous antigen specific TCRs, and engineered TCRs. Further we discuss the development of low and high affinity TCRs and the extent to which each challenges central tolerance. Current results suggest that adaptation of TCR engineering of moderate affinity TCRs coupled with co-regulatory and stimulatory molecules may be the safest and most efficacious road for TCR development aimed at tumor abolition.

Immunity. 2002 Mar;16(3):345-54. (PMID: 11911820)
Nat Immunol. 2014 Feb;15(2):186-94. (PMID: 24317039)
J Exp Med. 2011 Jun 6;208(6):1279-89. (PMID: 21606508)
J Immunother. 2013 Feb;36(2):133-51. (PMID: 23377668)
Nat Chem Biol. 2009 Oct;5(10):721-3. (PMID: 19718041)
Nature. 1993 Jul 1;364(6432):33-9. (PMID: 8316295)
Immunology. 2006 Jun;118(2):240-9. (PMID: 16771859)
J Immunother. 2010 Oct;33(8):840-7. (PMID: 20842052)
Immunology. 2009 Feb;126(2):165-76. (PMID: 19125887)
Front Immunol. 2013 Jun 19;4:154. (PMID: 23801991)
Cancer Res. 2008 Apr 15;68(8):2993-3000. (PMID: 18413769)
Clin Cancer Res. 2013 Oct 1;19(19):5300-9. (PMID: 24089443)
Annu Rev Immunol. 2006;24:571-606. (PMID: 16551260)
Cancer Res. 2009 Jul 1;69(13):5490-7. (PMID: 19570783)
Immunol Rev. 2014 Jan;257(1):250-63. (PMID: 24329802)
J Exp Med. 1999 Sep 6;190(5):705-15. (PMID: 10477554)
J Immunol. 1999 May 1;162(9):5317-26. (PMID: 10228007)
Immunity. 1996 Aug;5(2):125-35. (PMID: 8769476)
Immunity. 2012 Oct 19;37(4):709-20. (PMID: 23084359)
Nat Immunol. 2009 Jun;10(6):610-7. (PMID: 19430476)
Front Immunol. 2012 Mar 21;3:51. (PMID: 22566933)
Front Immunol. 2013 Oct 11;4:326. (PMID: 24130560)
Onco Targets Ther. 2014 Feb 19;7:203-9. (PMID: 24570590)
Mol Ther. 2011 Mar;19(3):620-6. (PMID: 21157437)
J Immunol. 2004 Jan 1;172(1):104-13. (PMID: 14688315)
Science. 2014 May 9;344(6184):641-5. (PMID: 24812403)
Sci Transl Med. 2012 Aug 29;4(149):149ra120. (PMID: 22932225)
Nature. 2009 Mar 12;458(7235):211-4. (PMID: 19182777)
Cancer Gene Ther. 2014 Feb;21(2):45-7. (PMID: 24535159)
Nat Rev Immunol. 2004 Feb;4(2):123-32. (PMID: 15040585)
J Exp Med. 2008 Aug 4;205(8):1859-68. (PMID: 18625745)
Cold Spring Harb Perspect Biol. 2012 Jun;4(6). pii: a006957. doi: 10.1101/cshperspect.a006957. (PMID: 22661634)
Nat Immunol. 2001 Apr;2(4):301-6. (PMID: 11276200)
Immunity. 2009 Oct 16;31(4):621-31. (PMID: 19833087)
J Immunol. 2004 May 15;172(10):5967-72. (PMID: 15128778)
J Biol Chem. 2010 Dec 31;285(53):41525-32. (PMID: 21037289)
Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13574-9. (PMID: 16174747)
Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6458-62. (PMID: 8022805)
Blood. 2013 Aug 8;122(6):863-71. (PMID: 23770775)
J Exp Med. 2002 May 20;195(10):1279-88. (PMID: 12021308)
Cancer Microenviron. 2014 Aug;7(1-2):1-9. (PMID: 24357332)
J Exp Med. 1999 May 17;189(10):1531-44. (PMID: 10330432)
Nat Rev Immunol. 2009 Mar;9(3):207-13. (PMID: 19151748)
Science. 2008 Oct 10;322(5899):271-5. (PMID: 18845758)
Nat Immunol. 2005 Apr;6(4):345-52. (PMID: 15785760)
Front Immunol. 2013 Oct 11;4:324. (PMID: 24133495)
J Exp Med. 2012 Sep 24;209(10):1769-79. (PMID: 22987800)
Science. 1986 Sep 19;233(4770):1318-21. (PMID: 3489291)
Sci Signal. 2011 Dec 20;4(204):ra90. (PMID: 22375050)
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20422-7. (PMID: 19088187)
Nat Med. 2013 Jun;19(6):747-52. (PMID: 23644516)
J Exp Med. 2009 Sep 28;206(10):2121-30. (PMID: 19737865)
Nature. 2006 Feb 9;439(7077):682-7. (PMID: 16382236)
Immunity. 1995 Nov;3(5):541-7. (PMID: 7584144)
J Immunol. 2007 Sep 15;179(6):3578-87. (PMID: 17785792)
Immunity. 1999 Aug;11(2):141-51. (PMID: 10485649)
J Exp Med. 2009 Dec 21;206(13):3015-29. (PMID: 20008522)
Nat Rev Cancer. 2012 Apr;12(4):252-64. (PMID: 22437870)
Nat Immunol. 2001 Nov;2(11):1032-9. (PMID: 11600886)
Biophys J. 2005 Sep;89(3):2121-33. (PMID: 15980174)
J Immunol. 1987 Feb 1;138(3):989-95. (PMID: 3100623)
Nat Immunol. 2001 Mar;2(3):229-34. (PMID: 11224522)
Front Immunol. 2013 Nov 08;4:363. (PMID: 24265631)
J Exp Med. 2004 Jan 19;199(2):155-66. (PMID: 14734521)
J Clin Invest. 2014 May;124(5):2246-59. (PMID: 24667641)
J Immunol. 2009 Oct 15;183(8):4848-52. (PMID: 19801511)
Clin Cancer Res. 2010 Dec 15;16(24):6122-31. (PMID: 20668005)
Immunity. 1998 Dec;9(6):817-26. (PMID: 9881972)
Science. 2002 Oct 25;298(5594):850-4. (PMID: 12242449)
J Immunol. 2003 Sep 15;171(6):3287-95. (PMID: 12960359)
Elife. 2014;3:e01310. (PMID: 24596147)
Cancer Immunol Res. 2013 Aug;1(2):99-111. (PMID: 24459675)
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6973-8. (PMID: 23576742)
Cell. 2006 Jul 28;126(2):253-6. (PMID: 16873058)
Nature. 1996 Jun 13;381(6583):616-20. (PMID: 8637599)
Nature. 2013 Dec 19;504(7480):441-5. (PMID: 24226767)
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13009-14. (PMID: 18755889)
Immunol Rev. 2014 Jan;257(1):72-82. (PMID: 24329790)
J Biol Chem. 2007 Aug 17;282(33):23799-810. (PMID: 17540778)
Adv Immunol. 2006;90:215-41. (PMID: 16730265)
J Immunol. 2008 Feb 1;180(3):1442-50. (PMID: 18209039)
J Biol Chem. 2012 Jun 29;287(27):23068-78. (PMID: 22549784)
Nat Med. 1999 Jun;5(6):677-85. (PMID: 10371507)
Science. 1996 Aug 16;273(5277):963-6. (PMID: 8688082)
Transl Res. 2013 Apr;161(4):365-79. (PMID: 23246626)
J Immunol. 2001 Oct 15;167(8):4271-5. (PMID: 11591749)
Cancer Res. 2013 Jan 15;73(2):595-604. (PMID: 23204239)
J Mol Biol. 2005 Feb 11;346(1):223-39. (PMID: 15663940)
J Exp Med. 2000 Dec 4;192(11):1637-44. (PMID: 11104805)
J Immunol. 2007 Sep 1;179(5):2952-60. (PMID: 17709510)
Immunity. 1998 Mar;8(3):319-29. (PMID: 9529149)
J Theor Biol. 2007 Nov 21;249(2):395-408. (PMID: 17869274)
Nature. 1999 Nov 18;402(6759):255-62. (PMID: 10580495)
Immunol Rev. 2009 Sep;231(1):210-24. (PMID: 19754899)
J Immunol. 2006 Nov 15;177(10):6769-79. (PMID: 17082590)
Science. 2007 Mar 23;315(5819):1687-91. (PMID: 17332376)
J Immunol. 2006 Jul 1;177(1):40-4. (PMID: 16785496)
Target Oncol. 2012 Mar;7(1):3-14. (PMID: 22350487)

Keywords: AIRE, autoimmune regulator; CDR, complementarity determining region; CTA, cancer testis antigen; MHC, major histocompatibility complex; SLEC, short-lived effector cell; T cell receptor; TAA, tumor-associated antigen; TCR, T cell receptor; TIL, tumor infiltrating lymphocyte; TSA, tissue-specific self-antigen; adoptive cell therapy; affinity; cancer; co-receptor; mTEC, medullary thymic epithelial cell; tumor

0 (Receptors, Antigen, T-Cell, alpha-beta)

Date Created: 20141209 Date Completed: 20151023 Latest Revision: 20181113

20240829

PMC4514023

10.4161/21645515.2014.973314

25483644